Table 2.
Univariate and multivariate Cox regression analyses for the prediction of disease recurrence in NMIBC patients treated with intravesical BCG
| NMIBC patients | Univariate analyses |
Multivariate analyses |
||||
|---|---|---|---|---|---|---|
| HR | 95% CI | p value | HR | 95% CI | p value | |
| Age | 1.093 | 1.030–1.159 | 0.003 | 0.991 | 0.930–1.055 | 0.769 |
| Gender (male vs female) | 1.748 | 0.405–7.533 | 0.454 | |||
| Smoking history (smoker vs nonsmoker) | 0.711 | 0.233–2.173 | 0.549 | |||
| PS (1 vs 0) | 0.862 | 0.115–6.442 | 0.885 | |||
| Cytology (IV + V vs II + III) | 4.841 | 1.897–12.355 | <0.001 | 2.692 | 0.748–9.692 | 0.130 |
| Recurrence history (recurrent vs primary) | 3.222 | 1.170–8.872 | 0.024 | 2.499 | 0.592–10.549 | 0.213 |
| Second TURBT (yes vs no) | 0.641 | 0.233–0.763 | 0.389 | |||
| cT (cT1 vs cTa) | 1.091 | 0.603–0.974 | 0.774 | |||
| Tumor grade (high vs low) | 1.122 | 0.431–2.921 | 0.813 | |||
| CIS (positive vs negative) | 1.866 | 0.743–4.685 | 0.184 | |||
| Immediate postoperative instillation of intravesical chemotherapy (yes vs no) | 1.816 | 0.690–4.779 | 0.227 | |||
| BCG strain (Connaught vs Tokyo172) | 0.304 | 0.120–0.770 | 0.012 | 0.424 | 0.142–1.267 | 0.125 |
| Maintenance BCG (yes vs no) | 0.162 | 0.022–1.210 | 0.076 | |||
| Total number of BCG instillations | 0.986 | 0.883–1.101 | 0.805 | |||
| EORTC recurrence risk | 1.388 | 0.781–2.466 | 0.265 | |||
| CUETO recurrence risk | 2.154 | 1.305–3.557 | 0.003 | 1.459 | 0.529–4.024 | 0.466 |
| MTC-PCR | 63.050 | 20.131–197.473 | <0.001 | 36.782 | 10.072–134.321 | <0.001 |
BCG = bacillus Calmette-Guérin; CI = confidence interval; CIS = carcinoma in situ; cT = clinical T disease; CUETO = Club Urologico Espanol de Tratamiento Oncologico; EORTC = European Organization for Research and Treatment of Cancer; HR = hazard ratio; MTC-PCR = urine M. tuberculosis complex polymerase chain reaction; NMIBC = non–muscle-invasive bladder cancer; PS = performance status; TURBT = transurethral resection of bladder tumor.